<DOC>
	<DOCNO>NCT00770302</DOCNO>
	<brief_summary>Saxagliptin new investigational medication develop treatment type 2 diabetes . This Phase I study design ass pharmacokinetics saxagliptin pharmacologically active metabolite , BMS-510849 , follow single multiple oral dos 5 mg saxagliptin healthy Chinese subject .</brief_summary>
	<brief_title>Assess Pharmacokinetics , Safety Tolerability Healthy Chinese Volunteers After Oral Doses Saxagliptin</brief_title>
	<detailed_description />
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Men woman ( childbearing potential ) Chinese ethnicity Weigh least 50 kg body mass index ( BMI ) 19 24 kg/m2 Must normal physical examination , laboratory value , ECG , pulse blood pressure unless investigator considers abnormality clinically significant . History clinically significant hypoglycaemia ( low blood sugar level ) Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>HBA1c</keyword>
	<keyword>Incretins</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>